Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis

• Published in: Current medical research and opinion 2005-05, Vol.21 (5), p.683-691
• Main Authors: Abelson, Mark B., Gomes, Paul J., Vogelson, Cullen T., Pasquine, Terri A., Turner, F. Darell, Wells, David T., Robertson, Stella M.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Allergic conjunctivitis; Allergic rhinitis; Allergic rhinoconjunctivitis; Child; Conjunctivitis, Allergic - drug therapy; Dibenzoxepins - administration & dosage; Dibenzoxepins - therapeutic use; Female; Histamine H1 Antagonists - administration & dosage; Histamine H1 Antagonists - therapeutic use; Humans; Male; Middle Aged; Nasal; Ocular allergy; Olopatadine; Olopatadine Hydrochloride; Ophthalmic Solutions; Placebos; Rhinitis, Allergic, Perennial - drug therapy
• ISSN: 0300-7995; 1473-4877
• DOI: 10.1185/030079905X43622

Background: A new formulation of olopatadine hydrochloride ophthalmic solution (olopatadine 0.2%) was evaluated in two separate, randomized, placebo-controlled, double-masked, hybrid environmental studies intended to determine efficacy and safety in subjects with histories of seasonal allergic conjunctivitis or rhinoconjunctivitis. Design and methods: In these 10- and 12-week trials (conducted April-August 2003 and July-December 2001, respectively), subjects assessed their ocular signs and symptoms. Additionally, subjects in the 10-week trial evaluated the frequency of their nasal symptoms while subjects in the 12-week trial evaluated both the frequency and severity of their nasal symptoms. The two trials had a combined enrollment of 500 subjects (217 males, 283 females) including 44 children aged 10-17 years; the combined population was 81.4% Caucasian, 9.2% Black, 2% Hispanic, and 7.4% other. Daily throughout these studies, either ragweed (fall study) or grass (spring study) pollen counts were obtained from each investigative center. Slope analyses were conducted on the nasal symptom assessments by pollen count. Results: The nasal results from the two clinical trials are presented herein. In the fall study, relative to placebo, olopatadine 0.2% significantly reduced the frequency of pollen effects on sneezing (p = 0.0355) and itchy nose (p = 0.0032), and reduced the severity of pollen effects on sneezing (p = 0.0451), itchy nose (p = 0.0178), and runny nose (p = 0.0327). In the spring study, olopatadine 0.2% significantly reduced the frequency of pollen effects on sneezing (p = 0.0017) and runny nose (p = 0.0031) relative to placebo. In the fall trial, 2 subjects discontinued due to treatment-related adverse events (tachycardia and dry eye), while in the spring study, no subject discontinued due to a treatment-related adverse event. No subject in either study suffered a treatment-related serious adverse event. Conclusions: For the subjects enrolled in these studies, olopatadine 0.2% appeared to be safe, well-tolerated, and effective in significantly reducing the frequency and/or severity of some effects of pollen on nasal symptoms.